24/7 Wall Street
05 Jan 2026, 15:33 UTC · 35w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
5 claims · each scored for market impact
AbbVie pays a $6.56 annual dividend against only $1.33 in diluted earnings per share, resulting in a 493% earnings payout ratio due to an 88.7% year-over-year earnings decline in Q3 2025 from the Humira patent cliff. — A 493% earnings payout ratio signals severe risk of a dividend cut for a major holding, which would pressure AbbVie's stock price and negatively impact funds holding it.
-0.70DHS's dividend payments declined from $3.53 in 2023 to $3.23 in 2025, representing an 8.5% decrease over two years. — A declining distribution directly undermines the core value proposition of a high-dividend ETF aimed at retirees, likely driving outflows from the fund.
-0.50Altria carries elevated risk with a 78% payout ratio and a negative book value of -$1.576, reflecting heavy debt from buybacks amid declining cigarette volumes and regulatory headwinds. — High payout ratios, negative book value, and structural volume declines constrain financial flexibility and increase the risk profile for a top portfolio holding.
-0.40Continue reading
5 related stories
Top 2 movers · tap to explore
Exxon Mobil demonstrates exceptional dividend safety, paying its $3.96 annual dividend from only 30% of its $55 billion operating cash flow, with $33.7 billion in net income providing substantial room for growth. — A well-covered, growing dividend from a major portfolio holding provides stability and positive return potential to the fund, mitigating risks from other positions.
+0.30Over 10 years, DHS gained 148% versus the S&P 500's 230%, significantly underperforming the broader market despite offering lower volatility and consistent income. — Significant long-term underperformance relative to the benchmark makes the fund less attractive for total-return investors and could lead to reallocation away from the ETF.
-0.30Which stocks this story touches
Demonstrates exceptional dividend safety, a fortress balance sheet, and strong net income.
Carries elevated risk due to declining cigarette volumes, regulatory headwinds, and negative book value.
Recommended as a quality alternative with better focus on dividend consistency and growth.
Facing significant earnings declines and a high payout ratio due to the Humira patent loss.
The fund has delivered strong total returns and stability for retirees, despite a slight decline in monthly distributions.
Mentioned as part of a problematic tobacco exposure for ESG-conscious investors.
Mentioned positively for generating a high yield.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
4h ago
